MeCure Industries Plc has opened a proposal of as much as N14 billion Series 8 Commercial Paper beneath its N40 billion Commercial Paper Programme.
The Lagos-based producer of medicines and multivitamins has been utilizing the market to lift cash for its short-term working capital wants.
This provide carries an implied annual yield of 21%. Investors holding the paper for its full 267-day length would earn roughly 15.36% on the quantity invested, earlier than relevant deductions, supplied MeCure repays in full.
The provide opened on Wednesday, October 14, 2026, and closes on Tuesday, October 20, 2026.
What the provide round is saying(*8*)
- Issuer: MeCure Industries Plc.
- Programme measurement: N40 billion.
- Series: 8 — goal measurement: Up to N14 billion.
- Tenor: 267 days.
- Discount fee: 18.2036% every year.
- Gross implied yield: 21% every year, acknowledged as inclusive of withholding tax.
- Allotment date: Tuesday, October 20, 2026.
- Settlement date: Wednesday, October 21, 2026.
- Maturity date: Thursday, July 15, 2027.
- Minimum subscription: N5 million and multiples of N1,000 thereafter.
- Issuer scores acknowledged in the provide: A1 from DataPro and A3 from GCR.
- Listing: Nigerian Exchange Limited and/or FMDQ Securities Exchange Limited.
The provide:(*8*)
The issuance follows MeCure’s provide of as much as N10 billion Series 7 commercial paper in February 2026, which carried a 269-day tenor and a gross annualised yield of 21.75%.
- The newest provide will increase the fundraising goal by N4 billion, whereas providing a yield 0.75 proportion factors decrease over an analogous interval.
- Proceeds will assist working capital, offering funding for the corporate’s operations whereas it converts manufacturing and gross sales into buyer receipts.
- Investors buy the paper beneath its reimbursement worth and obtain that worth at maturity.
On N5 million really invested, the acknowledged annualised yield would generate about N768,000 in gross earnings over 267 days, utilizing a 365-day calculation foundation.
Total proceeds can be roughly N5.768 million, earlier than relevant deductions and topic to full reimbursement.
Investment case(*8*)
MeCure’s 21% annual yield is increased than the 17.16% and 18.91% supplied by six-month and one-year Treasury payments on the October 14 public sale.
- Investors earn extra for lending to the corporate, though MeCure’s paper runs for a distinct interval of 267 days.
- The yield additionally stands above September’s 14.63% inflation fee, suggesting a possibility to develop cash sooner than costs. The precise profit will rely on taxes, charges and the way inflation modifications earlier than reimbursement.
- The extra necessary query is whether or not MeCure can repay.
MeCure’s announcement that it absolutely repaid its N3 billion bond in April 2026 affords some reassurance about its potential to honour debt obligations.
Its rising enterprise offers additional assist. Revenue elevated 20.4% to N44.85 billion in H1 2026, whereas decrease advertising and marketing bills helped working revenue rise sooner, by 41% to N10.90 billion.
- MeCure’s enlargement is rising its funding wants. The firm invested N16.69 billion in amenities and gear throughout H1 2026, effectively above the N1.45 billion in money generated from operations. Borrowing and present money helped fund the funding, leaving N2.07 billion in money at June.
- Total borrowings elevated 19.6% from December to N66.17 billion—about N3 borrowed for each N1 of shareholders’ funds.
- The rising debt burden provides to the significance of managing borrowing prices. Finance prices rose 54.9% to N5.93 billion, absorbing 54% of working revenue, in contrast with 49% a yr earlier.
MeCure’s working revenue nonetheless lined these prices, however they took a bigger share of its earnings regardless of the expansion in the enterprise.
The new amenities may assist reverse that pattern in the event that they generate sufficient extra gross sales and money to outpace the related prices. For CP buyers, reimbursement confidence will rely on these money receipts and the funding obtainable when the paper matures.
Investor takeaways(*8*)
The provide offers a gross annualised yield of 21%, equal to roughly 15.36% over 267 days.
- Sales and working revenue are rising, supporting the corporate’s earnings base.
- Expansion may strengthen future manufacturing and gross sales, however requires funding earlier than the complete advantages materialise.
Investors ought to verify internet earnings after relevant deductions and plan across the July 2027 maturity.
Risk concerns(*8*)
The principal concerns are rising financing prices, money dedicated to enlargement and the timing of buyer receipts.
- Further borrowing may take in a part of the profit from stronger working earnings.
- Slower collections or delays in producing returns from new capability may improve funding wants.
- Investors in search of to promote earlier than maturity could obtain a distinct return from the marketed yield.
Sustained money era and a transparent reimbursement funding plan would supply extra reassurance alongside MeCure’s earnings progress and acknowledged credit score scores.
